Navigation Links
EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Date:5/13/2008

ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Rodman and Renshaw 5th Annual Global Healthcare Conference, to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, May 19-20, 2008. Mr. Burns' presentation is scheduled for Monday, May 19, 2008 at 10:25 a.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

As previously mentioned, Mr. Burns' live presentation will be web cast and will serve as the Company's first quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatm
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. EntreMed Reports First Quarter 2008 Financial Results
2. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
3. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
4. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
5. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
6. EntreMed Reports Third Quarter 2007 Financial Results
7. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
8. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
9. EntreMed to Present at the Bio 2007 Investor Forum
10. EntreMed Receives Deloitte Technology Fast 50 Award
11. Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
... the number of foreign-born health care workers in... for transmitting tuberculosis in health-care sett...e experts Timothy R. Sterling, M.D., and David W. ...ed to health care workers with latent TB infection...
...arma company Venus Remedies Ltd today said it has ...or its latest antibiotic fixed dose combination us...w antibiotic combination, active against multi-res...and gram-negative bacteria and provides a broad-sp...
...ny adults who consider suicide fail to seek help f...en those who do ask for help may find it difficult...ording to a new study. "We need to improve access...ideation," said Ruth Klap, Ph.D., a sociologist at...
...e UNICEF has urged that the orphans and vulnerable...al fight against HIV/AIDS.// In their new report... AIDS', Unicef called for renewed vigour to tackle...realize the targets chartered in the UN Millennium...
Other Medicine News:Health News:Many Suicidal Adults Aren't Getting Mental Health Treatment 2
(Date:9/5/2008)...Calif., Sept. 5 /- SARcode,...lecule LFA-1 inhibitors,to treat inflammatory dise...NSS) today announced SARcode,s initiation of a Pha...uct candidate for T-cell mediated ophthalmic,disea...reement providing,SARcode with an exclusive licens...
(Date:9/5/2008)...microRNAs Extracted From a Simple Blood Draw Have,...rkers for a Wide Range of ..., Rosetta Genomics is Currently Developing ... REHOVOT, Israel and JERSEY CITY, New Jersey, Sept..., Ltd. (NASDQ: ROSG), a leader in,the development ...
(Date:9/4/2008)... designation for the treatment of Acute Myeloid ... N.J., Sept. 4 /- Celator Pharmaceuti...inistration (FDA) has granted orphan,drug designat...Injection,for the treatment of Acute Myeloid Leuke...duct two randomized Phase 2,studies with CPX-351. ...
(Date:9/4/2008)...aqMan(R) real-time PCR testing for the diagnostic ... Calif., Sept. 4 /- The U.S. Food & D...BAS(R) TaqMan(R) HBV Test,the first assay for qua...S.,The test uses Roche,s real-time PCR technology ... a patient,s blood. Doctors may use viral load,tes...
Breaking Medicine Technology:SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease 1582 1Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease 1582 2Cancer research giants collaborate to present the CTRC AACR San Antonio Breast Cancer Symposium 8198 1Cancer research giants collaborate to present the CTRC AACR San Antonio Breast Cancer Symposium 8198 2Cancer research giants collaborate to present the CTRC AACR San Antonio Breast Cancer Symposium 8198 3John Alexandrov Reveals the Secret to Financial Success Via Launch of The Power of Deliberate Creation Audio CDs 8194 1John Alexandrov Reveals the Secret to Financial Success Via Launch of The Power of Deliberate Creation Audio CDs 8194 2John Alexandrov Reveals the Secret to Financial Success Via Launch of The Power of Deliberate Creation Audio CDs 8194 3SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth 8189 1
...ND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS...th Pharmaceuticals, a,division of Wyeth (NYSE:WYE)...ata that showed that the safety profile of Enbrel(...in patients with,moderate-to-severe juvenile rheum...ars of therapy. JRA is a chronic autoimmune,diseas...
...TON, Mass.--(BUSINESS WIRE)--Jun 13, 2007 - EPIX,P...d that data from,its Phase 3 trial of PRX-00023, a... a poster presentation at the 47th Annual New,Clin...Raton,Florida. The meeting is sponsored by the Na...ty of Clinical Psychopharmacology., The presentati...
Other Medicine Technology:Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 2Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 3Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 4Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 5Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 6Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 7Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 8EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4
Excellent for manipulation of the intraocular lens in the capsular bag. The angled and curved shaft allows the instrument to reach across the implant and catch the optic/ haptic junction to facilitat
Angled shaft with 1.5 mm tip designed to efficiently perform the "Stop and Chop" technique. Round knurled handle. Most popular size or model.
This double ended instrument was designed for delineating and lifting the corneal flap of previously performed lamellar refractive surgery cases.
Used when dislocating the lens. Great for chopping during phacoemulsification. Helpful in ushering the IOL out of eye. Useful to reduce possibility of iris tuck with anterior chamber IOL placement.
Medicine Products: